MONITORING MULTIDIMENSIONAL ASPECTS OF QUALITY OF LIFE AFTER CANCER IMMUNOTHERAPY, AN OPEN SMART DIGITAL PLATFORM FOR PERSONALIZED PREVENTION AND PATIENT MANAGEMENT

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 875171.

1/01/2020 - 1/01/2024 (4 years)

HOSPICES CIVILS DE LYON FRANCE

VIEW PARTNERS >

HOSPICES CIVILS DE LYON, FRANCE

UNIVERSITE CLAUDE BERNARD LYON 1, FRANCE

UNIVERSITE LUMIERE LYON 2, FRANCE

CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE BESANCON, FRANCE

INSTITUTO PORTUGUES DE ONCOLOGIA DE LISBOA FRANCISCO GENTIL EPE, PORTUGAL

CONSORCI INSTITUT D’INVESTIGACIONS BIOMEDIQUES AUGUST PI I SUNYER, SPAIN

ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM, NETHERLANDS

LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE ROYAL CHARTER, UK

SCIENTIFIC ACADEMY FOR SERVICE TECHNOLOGY EV, GERMANY

EUROPEAN CANCER PATIENT COALITION, BELGIUM

ACADEMISCH ZIEKENHUIS GRONINGEN, NETHERLANDS

THE GENERAL HOSPITAL CORPORATION, USA

UNIVERSITA DELLA CALABRIA, ITALY

LYON INGENIERIE PROJETS, FRANCE

Why it matters

QUALITOP aims at developing a European immunotherapy-specific open Smart Digital Platform and using big data analysis, artificial intelligence, and simulation modelling approaches. This will enable collecting and aggregating efficiently real-world data to monitor health status and QoL of cancer patients given immunotherapy. Through causal inference analyses, QUALITOP will identify the determinants of health status regarding IR-AEs and define patient profiles in a real-world context. For this, heterogeneous data sources (big data), both retrospective and prospective –collected for QUALITOP from clinical centres in four EU countries—will integrate lifestyle, genetic, and psychosocial determinants of QoL. Using machine learning approaches, QUALITOP will provide “real-time” recommendations stemming from patient profiles and feedbacks via the Smart Digital Platform. Furthermore, an increased visibility on patients’ behaviour, a better IR-AEs prediction, and an improvement of care coordination will help analysing through simulation modelling approaches the gain in cost-effectiveness. Guidelines will be issued over the short and long-term.

“Qualitop aims at tackling one of the biggest challenges in patient care – the lack of real-life data on patients starting treatment, beyond clinical trials. By using an immunotherapy-specific open Smart Digital Platform and taking into account lifestyle, genetic, and psychosocial elements into a patient’s quality of life, this project ensures the progress already seen in immunotherapy will continue to go from strength to strength.”

Antonella Cardone, ECPC Director

What ECPC does

ECPC ‘s role is to continuously disseminate the communication around the Qualitop project as it progresses by overseeing and updating the Qualitop social media channels and website and ensuring the communication objectives are being reached. ECPC will collaborate closely with the project manager and the project coordinator and will involve each consortium member to implement the dissemination plan.

EU flag logo

This project is funded by the European Union